和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00013 和黄医药

已收盘 04-22 16:08:12

24.700

+2.600

+11.76%

最高25.100	最低21.950	成交量991.68万
今开22.100	昨收22.100	日振幅14.25%
总市值215.38亿	流通市值215.38亿	总股本8.72亿
成交额2.38亿	换手率1.14%	流通股本8.72亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00013","market":"HK","secType":"STK","nameCN":"和黄医药","latestPrice":24.7,"timestamp":1745309292011,"preClose":22.1,"halted":0,"volume":9916825,"delay":0,"floatShares":872000000,"shares":872000000,"eps":0.3421317985790078,"marketStatus":"已收盘","change":2.6,"latestTime":"04-22 16:08:12","open":22.1,"high":25.1,"low":21.95,"amount":238395975,"amplitude":0.142534,"askPrice":24.75,"askSize":4000,"bidPrice":24.7,"bidSize":24500,"shortable":3,"etf":0,"ttmEps":0.31025255189103657,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1745371800000},"marketStatusCode":5,"adr":0,"listingDate":1624982400000,"exchange":"SEHK","adjPreClose":22.1,"openAndCloseTimeList":[[1745285400000,1745294400000],[1745298000000,1745308800000]],"volumeRatio":1.493566,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00013","defaultTab":"news","newsList":[{"id":"2529292553","title":"每日卖空追踪 | 和黄医药 04月22日卖空量成交40.8万股，卖空比例为4.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529292553","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529292553?lang=zh_cn&edition=full","pubTime":"2025-04-22 16:30","pubTimestamp":1745310609,"startTime":"0","endTime":"0","summary":"和黄医药北京时间04月22日，涨11.76%，卖空量成交40.8万股，较上一交易日减少56.15%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422171900a6c38dee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422171900a6c38dee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00013","BK1587","BK1588","BK1191"],"gpt_icon":0},{"id":"2529394377","title":"国信证券：关注出海加速的创新药以及政策支持的服务板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2529394377","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529394377?lang=zh_cn&edition=full","pubTime":"2025-04-22 11:00","pubTimestamp":1745290808,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国信证券发布研报称，从2025年初以来，国产创新药企业已经完成了几十笔对外授权的交易，均与海外MNC达成了重磅交易。国产创新药的研发进度和临床数据越来越在全球范围内占到优势，创新药BD出海受关税影响较小，有望继续通过授权出海的形式实现全球的商业化价值。报告中称，2025年4月10日，国家医保局正式宣告中国医疗保险研究会生育保险专业委员会成立。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1282076.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348784397.USD","BK1583","BK0183","IE00BPRC5H50.USD","06978","IE00B5MMRT66.SGD","LU1794554557.SGD","00013","BK1588","BK0028","BK0188","BK0276","LU1720050803.USD","BK1574","LU2488822045.USD","09926","BK1191","IE00B543WZ88.USD","02162","06990","LU0417516571.SGD","002736","BK1587","LU0196878994.USD","LU0348783233.USD","01530","BK1593","BK1161","159992"],"gpt_icon":0},{"id":"2529977362","title":"和黄医药盘中异动 早盘急速上涨5.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529977362","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529977362?lang=zh_cn&edition=full","pubTime":"2025-04-22 09:34","pubTimestamp":1745285663,"startTime":"0","endTime":"0","summary":"2025年04月22日早盘09时34分，和黄医药股票出现异动，股价快速上涨5.20%。截至发稿，该股报23.250港元/股，成交量46.8万股，换手率0.05%，振幅5.88%。和黄医药股票所在的药品行业中，整体涨幅为0.24%。其相关个股中，三生制药、石药集团、远大医药涨幅较大，振幅较大的相关个股有石药集团、和黄医药、先声药业，振幅分别为7.19%、5.88%、5.74%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042209342394dd703a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042209342394dd703a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1588","BK1587","00013"],"gpt_icon":0},{"id":"2529366553","title":"【和黄医药(00013.HK)：赛沃替尼用于治疗MET扩增胃癌患者的II期研究的注册阶段已完成患者入组】智通财经APP讯，和黄医药(00013.HK)发布公告，赛沃替尼用于治疗MET扩增胃癌患者的II期研究的注册阶段已完成患者入组。","url":"https://stock-news.laohu8.com/highlight/detail?id=2529366553","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529366553?lang=zh_cn&edition=full","pubTime":"2025-04-22 08:36","pubTimestamp":1745282198,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药(00013.HK)发布公告，赛沃替尼用于治疗MET扩增胃癌患者的II期研究的注册阶段已完成患者入组。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/22083649734607.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU1989772840.SGD","BK1588","BK1191","BK4531","00013","LU1291159041.SGD","BK4007","BK4162","LU1496350502.SGD","LU1989772923.USD","BK4585","BK1587","LU1989771016.USD","BK4588","MET","HCM"],"gpt_icon":0},{"id":"2529365635","title":"和黄医药(00013)：赛沃替尼用于治疗MET扩增胃癌患者的II期研究的注册阶段已完成患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2529365635","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529365635?lang=zh_cn&edition=full","pubTime":"2025-04-22 08:28","pubTimestamp":1745281717,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 发布公告，赛沃替尼用于治疗MET扩增胃癌患者的II期研究的注册阶段已完成患者入组。如果研究取得积极结果，和黄医药有望于2025年年底在中国启动向国家药监局递交赛沃替尼用于治疗胃癌的上市许可申请。中国每年约新增18000例MET扩增的胃癌病例。目前正在进行中的注册研究是继多项赛沃替尼在亚洲治疗MET驱动的胃癌的II期研究后开展的，其中包括VIKTORY研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1282003.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","BK4531","LU1291159041.SGD","LU1989771016.USD","LU1989772923.USD","BK4588","BK1587","MET","HCM","BK1191","BK4162","BK4585","BK4007","00013","LU1496350502.SGD","LU1989772840.SGD"],"gpt_icon":0},{"id":"2529369592","title":"和黄医药：完成赛沃替尼(savolitinib)用于治疗胃癌的中国II期注册研究的患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2529369592","media":"格隆汇","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529369592?lang=zh_cn&edition=full","pubTime":"2025-04-22 08:16","pubTimestamp":1745281004,"startTime":"0","endTime":"0","summary":"格隆汇4月22日丨和黄医药发布公告，赛沃替尼用于治疗MET扩增胃癌患者的II期研究的注册阶段已完成患者入组。中国国家药品监督管理局已将赛沃替尼纳入突破性治疗药物品种，用于治疗既往接受过至少两线标准疗法失败的MET扩增的局部晚期或转移性胃癌或胃食管结合部腺癌患者。如果研究取得积极结果，和黄医药有望于2025年年底在中国启动向国家药监局递交赛沃替尼用于治疗胃癌的上市许可申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422081644a461ae7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422081644a461ae7b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1588","BK1587","00013"],"gpt_icon":0},{"id":"2527427264","title":"和黄医药04月16日主力净流出542万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2527427264","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527427264?lang=zh_cn&edition=full","pubTime":"2025-04-16 16:17","pubTimestamp":1744791432,"startTime":"0","endTime":"0","summary":"04月16日, 和黄医药股价跌3.33%，报收21.80元，成交金额1.09亿元，换手率0.58%，振幅5.99%，量比0.51。和黄医药今日主力资金净流出542万元，上一交易日主力净流入919万元。该股近5个交易日上涨5.61%，主力资金累计净流入710万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入9198万元，其中净流入天数为12日。该股主力净额占比0.03%，港股市场排名2475/2650。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416174249a45aeccb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416174249a45aeccb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00013","BK1588","BK1191","BK1587"],"gpt_icon":0},{"id":"2527770281","title":"和黄医药盘中异动 快速下挫5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527770281","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527770281?lang=zh_cn&edition=full","pubTime":"2025-04-16 11:13","pubTimestamp":1744773238,"startTime":"0","endTime":"0","summary":"2025年04月16日早盘11时13分，和黄医药股票出现波动，股价急速下跌5.10%。截至发稿，该股报21.400港元/股，成交量191.3万股，换手率0.22%，振幅4.88%。和黄医药股票所在的药品行业中，整体跌幅为0.50%。其相关个股中，兴科蓉医药、顺腾国际控股、三爱健康集团涨幅较大，振幅较大的相关个股有培力农本方、顺腾国际控股、君圣泰医药-B，振幅分别为10.20%、8.33%、7.55%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041611135897395bae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041611135897395bae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1588","00013","BK1587"],"gpt_icon":0},{"id":"2527138862","title":"每日卖空追踪 | 和黄医药 04月14日卖空量成交61.95万股，卖空比例为8.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527138862","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527138862?lang=zh_cn&edition=full","pubTime":"2025-04-14 16:30","pubTimestamp":1744619412,"startTime":"0","endTime":"0","summary":"和黄医药北京时间04月14日，涨6.98%，卖空量成交61.95万股，较上一交易日减少62.25%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250414171735a4584dca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250414171735a4584dca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1587","00013","BK1191","BK1588"],"gpt_icon":0},{"id":"2518219536","title":"和黄医药03月10日主力净流出1473万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2518219536","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518219536?lang=zh_cn&edition=full","pubTime":"2025-03-10 16:16","pubTimestamp":1741594567,"startTime":"0","endTime":"0","summary":"03月10日, 和黄医药股价跌4.07%，报收24.75元，成交金额1.41亿元，换手率0.65%，振幅7.36%，量比1.00。和黄医药今日主力资金净流出1473万元，上一交易日主力净流入855万元。该股近5个交易日下跌1.19%，主力资金累计净流出1022万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入9423万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310170101a269ba60&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310170101a269ba60&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1587","00013","BK1191","BK1588"],"gpt_icon":0},{"id":"2518431266","title":"和黄医药盘中异动 快速下挫5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518431266","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518431266?lang=zh_cn&edition=full","pubTime":"2025-03-10 11:51","pubTimestamp":1741578696,"startTime":"0","endTime":"0","summary":"2025年03月10日临近午盘11时51分，和黄医药股票出现异动，股价大幅跳水5.04%。截至发稿，该股报24.500港元/股，成交量270.671万股，换手率0.31%，振幅6.98%。和黄医药股票所在的药品行业中，整体跌幅为0.34%。其相关个股中，励晶太平洋、君圣泰医药-B、三生制药涨幅较大，振幅较大的相关个股有艾美疫苗、衍生集团、三生制药，振幅分别为14.51%、8.49%、7.27%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310115136a2695196&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310115136a2695196&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1587","BK1588","00013"],"gpt_icon":0},{"id":"2517374324","title":"美股异动 | 和黄医药(HCM.US)涨近4% 完成HMPL-453(fanregratinib)中国II期注册研究患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2517374324","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517374324?lang=zh_cn&edition=full","pubTime":"2025-03-07 23:55","pubTimestamp":1741362908,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周五，和黄医药涨近4%，报16.64美元。消息面上，3月6日，和黄医药公告，HMPL-453 用于治疗伴有成纤维细胞生长因子受体2融合/重排的肝内胆管癌患者的II期临床试验已完成患者入组。该研究是一项单臂、多中心、开放标签的II期注册研究，旨在评估HMPL-453用于治疗伴有FGFR2融合/重排的晚期肝内胆管癌患者的疗效、安全性和药代动力学。注册研究阶段共纳入87名患者 。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259400.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","BK1191","BK4531","00013","BK4007","BK4585","BK1587","BK4588","HCM"],"gpt_icon":0},{"id":"2517722103","title":"和黄医药03月07日主力净流入855万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2517722103","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517722103?lang=zh_cn&edition=full","pubTime":"2025-03-07 16:16","pubTimestamp":1741335383,"startTime":"0","endTime":"0","summary":"03月07日, 和黄医药股价涨1.57%，报收25.80元，成交金额1.74亿元，换手率0.77%，振幅8.07%，量比1.08。和黄医药今日主力资金净流入855万元，上一交易日主力净流出728万元。该股近5个交易日上涨0.19%，主力资金累计净流入1413万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入1.14亿元，其中净流入天数为13日。该股主力净额占比0.04%，港股市场排名189/2653。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307170501a263de17&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307170501a263de17&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00013","BK1191","BK1587","BK1588"],"gpt_icon":0},{"id":"2517986142","title":"和黄医药盘中异动 早盘股价大涨5.12%报26.700港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517986142","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517986142?lang=zh_cn&edition=full","pubTime":"2025-03-07 10:47","pubTimestamp":1741315643,"startTime":"0","endTime":"0","summary":"2025年03月07日早盘10时47分，和黄医药股票出现波动，股价急速上涨5.12%。截至发稿，该股报26.700港元/股，成交量256.45万股，换手率0.29%，振幅7.68%。资金方面，该股资金流入4043.36万港元，流出1784.55万港元。和黄医药股票所在的药品行业中，整体涨幅为0.01%。其相关个股中，和黄医药、九源基因、兴科蓉医药涨幅较大，振幅较大的相关个股有精优药业、开拓药业-B、李氏大药厂，振幅分别为7.84%、7.76%、7.63%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307104723a2635146&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307104723a2635146&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1587","00013","BK1191","BK1588"],"gpt_icon":0},{"id":"2517611248","title":"智通港股早知道 | 郑栅洁：今年将提出一批重大战略任务、重大政策举措和重大工程项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2517611248","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517611248?lang=zh_cn&edition=full","pubTime":"2025-03-07 07:27","pubTimestamp":1741303644,"startTime":"0","endTime":"0","summary":"香港证券市场市价总值于2025年2月底为39.1万亿港元，较上月底的35.4万亿港元上升10%，并较去年同期的30.1万亿港元上升30%。本集团预计该产品将于近期获中国国家药品监督管理局批准上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258853.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0762540952.USD","LU2257852520.SGD","BK1541","LU0197773160.USD","BK1502","LU0348735423.USD","02618","LU0348825331.USD","LU2039709279.SGD","LU1993786604.SGD","LU1734074674.USD","00066","LU0417516738.SGD","LU1366334578.USD","00388","HKXCY","LU1481107354.HKD","LU0650527681.SGD","LU0417516902.SGD","LU0164880469.USD","LU0630378692.HKD","YANG","LU0501845795.SGD","LU0043850808.USD","LU0211977185.USD","LU0918141887.USD","LU0072913022.USD","IE00BZ08YS42.EUR","LU0348827113.USD","LU0370786039.SGD","HSCEI","LU0348816934.USD","LU0456846285.SGD","00013","LU0572944931.SGD","80388","IE00BZ08YR35.GBP","LU1981816686.USD","LU0577902454.USD","LU0067412154.USD","LU0577902611.USD","LU0577902298.EUR","BK1587","HSTECH","IE00B3T34201.USD","01177","BK1131","LU2226246903.HKD","LU0251144936.SGD"],"gpt_icon":1},{"id":"2517327331","title":"和黄医药(00013)：完成HMPL-453 (fanregratinib) 用于治疗肝内胆管癌的中国II期注册研究的患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2517327331","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517327331?lang=zh_cn&edition=full","pubTime":"2025-03-06 18:08","pubTimestamp":1741255724,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 发布公告，HMPL-453 用于治疗伴有成纤维细胞生长因子受体2融合/重排的肝内胆管癌患者的II期临床试验已完成患者入组。该研究是一项单臂、多中心、开放标签的II期注册研究，旨在评估HMPL-453用于治疗伴有FGFR2融合/重排的晚期肝内胆管癌患者的疗效、安全性和药代动力学。注册研究阶段共纳入87名患者 。HMPL-453 是一种新型、高选择性且强效的FGFR 1 、2和3抑制剂。和黄医药目前拥有HMPL-453在全球范围内的所有权利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258643.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4531","HCM","BK1191","BK1588","BK4585","BK1587","00013","BK4007","BK4588"],"gpt_icon":0},{"id":"2517136985","title":"和黄医药03月06日遭主力抛售728万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517136985","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517136985?lang=zh_cn&edition=full","pubTime":"2025-03-06 16:16","pubTimestamp":1741248970,"startTime":"0","endTime":"0","summary":"03月06日, 和黄医药股价跌1.55%，报收25.40元，成交金额2.04亿元，换手率0.92%，振幅6.78%，量比1.20。和黄医药今日主力资金净流出728万元，上一交易日主力净流出64万元。该股近5个交易日下跌5.24%，主力资金累计净流出546万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入8420万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306165618a26229bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306165618a26229bf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","BK1587","BK1191","00013"],"gpt_icon":0},{"id":"2517944739","title":"和黄医药任命黄德伟为独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2517944739","media":"财中社","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517944739?lang=zh_cn&edition=full","pubTime":"2025-03-05 18:10","pubTimestamp":1741169423,"startTime":"0","endTime":"0","summary":"3月5日，和黄医药发布公告，宣布黄德伟被委任为公司独立非执行董事及审计委员会成员，自2025年3月6日起生效。根据他的聘任书，黄德伟作为独立非执行董事及审计委员会成员的薪酬分别为每年7.6万美元和1.35万美元，薪酬将依据董事职务与责任及市场情况进行调整，并按比例计算不足一年之任期的薪酬。此外，黄德伟确认与公司董事、高层管理人员及主要股东无任何关系，并满足香港上市规则的独立性要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305181114963a8f46&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305181114963a8f46&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","00013","BK1587","BK1588","HCM"],"gpt_icon":0},{"id":"2517994382","title":"和黄医药(00013)：黄德伟获任独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2517994382","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517994382?lang=zh_cn&edition=full","pubTime":"2025-03-05 18:04","pubTimestamp":1741169076,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药(00013)发布公告，黄德伟先生获委任为公司独立非执行董事及审核委员会成员，自2025年3月6日起生效。和黄医药主席艾乐德博士表示：“本人谨代表董事会热烈欢迎黄先生加入公司。我们相信，他在财务及会计的丰富经验将为公司的策略增长及财务管理作出重大贡献。”","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258088.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00013","BK1588","BK4531","BK1587","BK1191","BK4585","HCM","BK4588","BK4007"],"gpt_icon":0},{"id":"2516688675","title":"上海医药拟收购和黄医药10%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2516688675","media":"经济观察报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516688675?lang=zh_cn&edition=full","pubTime":"2025-03-03 16:50","pubTimestamp":1740991800,"startTime":"0","endTime":"0","summary":"公司动态　　经济观察网讯 3月2日，上海医药（601607.SH）发布公告，拟以约9.95亿元（以最终国资备案价格为准）收购和黄药业10%股权。目前上海医药已持有和黄药业50%股权，此次交易完成后，其持有持股将达60%，并实现并表。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2025-03-03/doc-inenkmne9161691.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2025-03-03/doc-inenkmne9161691.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4531","BK4585","BK4007","BK0099","HCM","00013","BK0175","BK1587","BK1197","BK0196","BK0028","BK0097","BK4588","BK1588","BK0184","BK0209","BK0020","BK1191","BK0183","BK0012","02607","BK0187","BK0188","601607"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hutch-med.com","stockEarnings":[{"period":"1week","weight":0.0549},{"period":"1month","weight":-0.0515},{"period":"3month","weight":0.0045},{"period":"6month","weight":-0.3313},{"period":"1year","weight":-0.1676},{"period":"ytd","weight":-0.02}],"compareEarnings":[{"period":"1week","weight":0.0345},{"period":"1month","weight":-0.1352},{"period":"3month","weight":0.0925},{"period":"6month","weight":0.0284},{"period":"1year","weight":0.3165},{"period":"ytd","weight":0.0666}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和黄医药（中国）有限公司是一间主要从事制造及销售药物的投资控股公司。该公司主要通过两个分部运营业务。肿瘤免疫业务分部从事发现、开发和商业化用于治疗癌症和免疫性疾病的靶向疗法和免疫疗法。其中研发包括涵盖药物发现、开发、生产及监管职能的研发活动，上市产品包括通过研发活动开发的药物的已开具发票的销售、推广、生产及分销。其他业务分部从事其他商业化业务，包括其他处方药物及保健品的销售、推广、生产及分销。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.116447},{"month":2,"riseRate":0.75,"avgChangeRate":0.102065},{"month":3,"riseRate":0.25,"avgChangeRate":-0.11719},{"month":4,"riseRate":0.5,"avgChangeRate":0.018984},{"month":5,"riseRate":0,"avgChangeRate":-0.194502},{"month":6,"riseRate":0.333333,"avgChangeRate":0.018958},{"month":7,"riseRate":1,"avgChangeRate":0.135989},{"month":8,"riseRate":0.25,"avgChangeRate":-0.055482},{"month":9,"riseRate":0.5,"avgChangeRate":-0.020796},{"month":10,"riseRate":0.25,"avgChangeRate":-0.032252},{"month":11,"riseRate":0.5,"avgChangeRate":0.182346},{"month":12,"riseRate":0.5,"avgChangeRate":-0.016836}],"exchange":"SEHK","name":"和黄医药","nameEN":"HUTCHMED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和黄医药,00013,和黄医药股票,和黄医药股票老虎,和黄医药股票老虎国际,和黄医药行情,和黄医药股票行情,和黄医药股价,和黄医药股市,和黄医药股票价格,和黄医药股票交易,和黄医药股票购买,和黄医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}